Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma

Next Previous
Trial Profile

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibrutinib (Primary) ; Antifungals; Cytarabine; Dexamethasone; Doxorubicin liposomal; Etoposide; Isavuconazole; Methotrexate; Rituximab; Temozolomide
  • Indications CNS cancer; Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 13 Dec 2022 Results from NCT02203526 and NCT03964090; assessing effect of Isavuconazole on Plasma and CSF Levels of Ibrutinib and Plasma Levels of Liposomal Doxorubicin, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 07 Dec 2022 Planned End Date changed from 15 Jun 2023 to 15 Jun 2024.
    • 07 Dec 2022 Planned primary completion date changed from 15 Jun 2023 to 15 Jun 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top